Culine S et al. Alternative bimonthly
cycles of doxorubicin, cyclophosphamide, and etoposide,
cisplatin with hematopoietic growth factor support in patients
with carcinoma of unknown primary site. Cancer
2002;94(3):840-6. Abstract.
Elkordy M et al. A phase II study of weekly paclitaxel
(Taxol®) and carboplatin in advanced carcinoma of unknown
primary origin. Proc ASCO 2001:Abstract
1603.
Fizazi K et al. Carcinoma of unknown primary (CUP):
Are the tyrosine kinase receptors HER- 2, EGF-R, and c-Kit
suitable targets for therapy? Proc ASCO 2003;Abstract
3549.
Greco FA et al. Carcinoma of unknown primary site. Cancer
2000;89(12):2655-60. Abstract.
Greco FA et al. Carcinoma of unknown primary site:
Phase II trials with docetaxel plus cisplatin or carboplatin. Ann
Oncol 2000;11(2):211-5. Abstract.
Greco FA et al. Gemcitabine, carboplatin, and paclitaxel
for patients with carcinoma of unknown primary site: A
Minnie Pearl Cancer Research Network study. J
Clin Oncol 2002;20(6):1651-6. Abstract.
Greco FA et al. Taxane-based chemotherapy for patients
with carcinoma of unknown primary site. Cancer
J 2001;7(3):203-12. Abstract.
Guardiola E et al. Combination of cisplatin-doxorubicin-cyclophosphamide
in adenocarcinoma of unknown primary site: A phase II trial. Am
J Clin Oncol 2001;24(4):372-5. Abstract.
Hainsworth JD et al. Gemcitabine in the second-line
therapy of patients with carcinoma of unknown primary site:
A phase II trial of the Minnie Pearl Cancer Research Network. Cancer
Invest 2001;19(4):335-9. Abstract.
Hainsworth JD, Greco FA. Management of patients
with cancer of unknown primary site. Oncology
(Huntingt) 2000;14(4):563-74;discussion 574-6, 578-9. Abstract.
Karapetis CS et al. Epirubicin, cisplatin, and
prolonged or brief infusional 5-fluorouracil in the treatment
of carcinoma of unknown primary site. Med Oncol
2001;18(1):23-32. Abstract.
Macdonald AG et al. A phase II study of mitomycin
C, cisplatin and continuous infusion 5- fluorouracil (MCF)
in the treatment of patients with carcinoma of unknown
primary site. Br J Cancer 2002;86(8):1238-42.
Abstract.
Mahomed R et al. Age as a prognostic factor in
metastatic cancer of unknown primary (CUP). Long term follow
up results. Proc ASCO 2003;Abstract
3590.
Mukai H et al. A safety and efficacy trial of docetaxel
(D) and cisplatin (P) in patients with cancer of unknown
primary (CUP). Proc ASCO 2003;Abstract
2597.
Saghatchian M et al. Carcinoma of an unknown primary
site: A chemotherapy strategy based on histological differentiation – Results
of a prospective study. Ann Oncol 2001;12(4):535-40.
Abstract.
Sumi H et al. Treatable subsets in cancer of unknown
primary origin. Proc ASCO 2000:Abstract 2279D.
Abstract.
Veach SR et al. Cancer of unknown primary, trends
in diagnosis and care. Proc ASCO 2003;Abstract
2238.
Voog E et al. Multicentric phase II study of cisplatin
and etoposide in patients with metastatic carcinoma of
unknown primary. Am J Clin Oncol 2000;23(6):614-6.
Abstract.
|
